HALOZYME THERAPEUTICS, INC. HALO revenue by segment, product and geography
In its fiscal year ending 2025-12-31, HALOZYME THERAPEUTICS, INC. reported revenue across 10 products and services; the largest, Royalty, was $868M (+52.0% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Royalty$868Mshare n/a+52.0% yoy
- Product$376Mshare n/a+24.0% yoy
- Proprietary Products Sales$195Mshare n/a+16.8% yoy
- Collaborative Agreements$152Mshare n/a+8.2% yoy
- Bulk R Hu PH20$133Mshare n/a+54.1% yoy
- Salesbasedmilestone$70Mshare n/a+133.3% yoy
- Device Partnered Products$48.8Mshare n/a-3.4% yoy
- Event Based Development And Regulatory Milestone And Other Fees$47Mshare n/a-35.2% yoy
- +2 more members in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Royalty$241Mshare n/a+43.1% yoy
- Product$130Mshare n/a+67.1% yoy
- Bulk R Hu PH20$73.5Mshare n/a+172.0% yoy
- Proprietary Products Sales$41.9Mshare n/a+15.2% yoy
- Device Partnered Products$15.1Mshare n/a+2.6% yoy
- Collaborative Agreements$5.6Mshare n/a-69.9% yoy
- +3 more members in the filing
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.